SAG
AXSM icon

SageView Advisory Group’s Axsome Therapeutics AXSM Stock Holding History

SageView Advisory Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$6.03K Buy
+33
New +$4.61K ﹤0.01% 1906

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SageView Advisory Group's AXSM Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Axsome Therapeutics (AXSM) in Q4 2025: 33 shares worth $6.03K. The stake represents ﹤0.01% of the portfolio and ranks #1906 among its holdings.

398 funds tracked by Wall St. Rank hold AXSM as of Q4 2025.

  • SageView Advisory Group held 33 shares of Axsome Therapeutics worth $6.03K as of Q4 2025.
  • Axsome Therapeutics was a new SageView Advisory Group position in Q4 2025.
  • Axsome Therapeutics made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #1906 holding.
  • 398 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.